HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial

Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium* SummaryBackground Observational and laboratory studies suggest that some hormonal contraceptive methods, particularly intramuscular depot medroxyprogesterone acetate (DMPA-IM), might increase women’s susceptibility to HIV acquisition. We aimed to compare DMPA-IM, a…

Planning for Outcomes (P4O) Modeling Tool: Estimating the Impact of Changing the Proportion of Injectable Progestins in the Contraceptive Method Mix

Planning for Outcomes (P4O) Modeling Tool: Estimating the Impact of Changing the Proportion of Injectable Progestins in the Contraceptive Method Mix

Elena Lebetkin, Xiaoming Gao, Douglas Taylor, Lauren Y. Maldonado, Abdulmumin Saad, Markus J. Steiner, Laneta J. Dorflinger, Kavita Nanda and Timothy D. Mastro Global Health: Science and Practice June 2019, GHSP-D-19-00062; https://doi.org/10.9745/GHSP-D-19-00062 ABSTRACTBackground: Observational studies raise concern about a potential link between injectable progestin contraceptive use and HIV acquisition risk. This possible…